| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702919 | American Journal of Ophthalmology | 2017 | 33 Pages |
Abstract
Intravitreal aflibercept TAE therapy led to significant visual improvement in eyes with NVAMD at 1 year, with some loss in the visual gains at the end of year 2 that was not related to loss of exudative control. TAE therapy with aflibercept is a rational strategy to reduce treatments and clinic evaluations over 2 years with satisfactory outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Francis Char DeCroos, David Reed, Murtaza K. Adam, David Salz, Omesh P. Gupta, Allen C. Ho, Carl D. Regillo,